Strategy's Bitcoin accumulation model faces a critical test as its modified net asset value (mNAV) drops below 1.0, meaning the company's stock now trades below the value of its Bitcoin reserves. This undermines the previous strategy of issuing shares at a premium to buy more Bitcoin, complicating future capital raises and increasing financing costs. Despite the recent Bitcoin price dip putting recent purchases at a loss, the company continues to accumulate Bitcoin, led by Michael Saylor. Going forward, Strategy must balance between buying Bitcoin at lower prices and preserving its financial stability amid rising costs and market skepticism.
Constellation Brands reported earnings per share of $3.74, surpassing analyst estimates of $3.55, and revenue of $2.63 billion, exceeding the $2.54 billion forecast. The company saw a 5% increase in beer sales and a 17% rise in wine and spirits sales...
U.S. spot Solana ETFs experienced $3.7 million in net outflows on October 6, marking the second consecutive day of withdrawals. The Grayscale Solana Trust was the main contributor to this decline, while six other funds showed no net flow. Although th...
Tilray Brands will announce its fiscal Q1 2027 earnings on October 8, with analysts forecasting a loss of $0.16-$0.19 per share on revenues around $265-$268 million, marking about 26% growth from last year. Investors will focus on cannabis and bevera...
On October 6, 2026, five notable stocks surged between 20.9% and 52.7%, driven by various positive developments. Apimeds Pharmaceuticals rose 52.7% after its subsidiary signed a blockchain contract, while Option Care Health gained 32.7% following a $...
On October 6, five notable stocks saw significant declines, with losses ranging from 17.5% to 50.1%. ArriVent BioPharma's shares plunged 46.9% after its lung cancer treatment failed to meet the primary endpoint in a Phase 3 trial. Armada Acquisition ...
